Logo image of IONS

IONIS PHARMACEUTICALS INC (IONS) Stock Price, Quote, News and Overview

NASDAQ:IONS - Nasdaq - US4622221004 - Common Stock - Currency: USD

31.86  -1.79 (-5.31%)

After market: 32.73 +0.87 (+2.73%)

IONS Quote, Performance and Key Statistics

IONIS PHARMACEUTICALS INC

NASDAQ:IONS (5/6/2025, 8:17:10 PM)

After market: 32.73 +0.87 (+2.73%)

31.86

-1.79 (-5.31%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High52.34
52 Week Low23.95
Market Cap5.07B
Shares159.04M
Float154.89M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)07-30 2025-07-30/bmo
IPO05-17 1991-05-17


IONS short term performance overview.The bars show the price performance of IONS in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 10 -10

IONS long term performance overview.The bars show the price performance of IONS in the last 1, 2 and 3 years. 1 year 2 years 3 years -5 -10 -15 -20

The current stock price of IONS is 31.86 USD. In the past month the price increased by 15.56%. In the past year, price decreased by -18.47%.

IONIS PHARMACEUTICALS INC / IONS Daily stock chart

IONS Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 18.22 331.06B
AMGN AMGEN INC 13.03 145.40B
GILD GILEAD SCIENCES INC 12.65 121.86B
VRTX VERTEX PHARMACEUTICALS INC N/A 115.69B
REGN REGENERON PHARMACEUTICALS 12.6 60.30B
ARGX ARGENX SE - ADR 323.74 37.56B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 35.10B
ONC BEIGENE LTD-ADR N/A 26.06B
BNTX BIONTECH SE-ADR N/A 22.77B
NTRA NATERA INC N/A 21.14B
SMMT SUMMIT THERAPEUTICS INC N/A 17.97B
BIIB BIOGEN INC 7.38 17.12B

About IONS

Company Profile

IONS logo image Ionis Pharmaceuticals, Inc. engages in the development and commercialization of human therapeutic drugs using antisense technology. The company is headquartered in Carlsbad, California and currently employs 1,069 full-time employees. Its marketed medicines consist of TRYNGOLZA, WAINUA (eplontersen), SPINRAZA (nusinersen), QALSODY (tofersen), TEGSEDI (inotersen) and WAYLIVRA (volanesorsen). TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS). WAINUA is approved for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults. SPINRAZA is used for the treatment of pediatric and adult patients with spinal muscular atrophy. QALSODY is approved for the treatment of Amyotrophic Lateral Sclerosis in adults who have a mutation in the superoxide dismutase 1 (SOD1) gene, or SOD1-ALS. TEGSEDI is approved for the treatment of ATTRv-PN in adults. WAYLIVRA is approved as an adjunct to diet in adult patients with genetically confirmed FCS and at high risk of acute, potentially fatal pancreatitis.

Company Info

IONIS PHARMACEUTICALS INC

2855 Gazelle Court

Carlsbad CALIFORNIA 92010 US

CEO: Brett P. MONIA

Employees: 1069

IONS Company Website

IONS Investor Relations

Phone: 17609319200

IONIS PHARMACEUTICALS INC / IONS FAQ

What is the stock price of IONIS PHARMACEUTICALS INC today?

The current stock price of IONS is 31.86 USD. The price decreased by -5.31% in the last trading session.


What is the ticker symbol for IONIS PHARMACEUTICALS INC stock?

The exchange symbol of IONIS PHARMACEUTICALS INC is IONS and it is listed on the Nasdaq exchange.


On which exchange is IONS stock listed?

IONS stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for IONIS PHARMACEUTICALS INC stock?

32 analysts have analysed IONS and the average price target is 59.16 USD. This implies a price increase of 85.67% is expected in the next year compared to the current price of 31.86. Check the IONIS PHARMACEUTICALS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is IONIS PHARMACEUTICALS INC worth?

IONIS PHARMACEUTICALS INC (IONS) has a market capitalization of 5.07B USD. This makes IONS a Mid Cap stock.


How many employees does IONIS PHARMACEUTICALS INC have?

IONIS PHARMACEUTICALS INC (IONS) currently has 1069 employees.


What are the support and resistance levels for IONIS PHARMACEUTICALS INC (IONS) stock?

IONIS PHARMACEUTICALS INC (IONS) has a support level at 31.85 and a resistance level at 32.79. Check the full technical report for a detailed analysis of IONS support and resistance levels.


Is IONIS PHARMACEUTICALS INC (IONS) expected to grow?

The Revenue of IONIS PHARMACEUTICALS INC (IONS) is expected to grow by 7.07% in the next year. Check the estimates tab for more information on the IONS EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy IONIS PHARMACEUTICALS INC (IONS) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does IONIS PHARMACEUTICALS INC (IONS) stock pay dividends?

IONS does not pay a dividend.


When does IONIS PHARMACEUTICALS INC (IONS) report earnings?

IONIS PHARMACEUTICALS INC (IONS) will report earnings on 2025-07-30, before the market open.


What is the Price/Earnings (PE) ratio of IONIS PHARMACEUTICALS INC (IONS)?

IONIS PHARMACEUTICALS INC (IONS) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.81).


What is the Short Interest ratio of IONIS PHARMACEUTICALS INC (IONS) stock?

The outstanding short interest for IONIS PHARMACEUTICALS INC (IONS) is 9.4% of its float. Check the ownership tab for more information on the IONS short interest.


IONS Technical Analysis

ChartMill assigns a technical rating of 3 / 10 to IONS. When comparing the yearly performance of all stocks, IONS is a bad performer in the overall market: 64.83% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

IONS Fundamental Analysis

ChartMill assigns a fundamental rating of 3 / 10 to IONS. The financial health of IONS is average, but there are quite some concerns on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

IONS Financial Highlights

Over the last trailing twelve months IONS reported a non-GAAP Earnings per Share(EPS) of -2.81. The EPS decreased by -5.24% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -15.11%
ROE -77.15%
Debt/Equity 2.12
Chartmill High Growth Momentum
EPS Q2Q%23.47%
Sales Q2Q%10.92%
EPS 1Y (TTM)-5.24%
Revenue 1Y (TTM)-7.59%

IONS Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 80% to IONS. The Buy consensus is the average rating of analysts ratings from 32 analysts.

For the next year, analysts expect an EPS growth of -28.17% and a revenue growth 7.07% for IONS


Ownership
Inst Owners103.97%
Ins Owners0.79%
Short Float %9.4%
Short Ratio8.16
Analysts
Analysts80
Price Target59.16 (85.69%)
EPS Next Y-28.17%
Revenue Next Year7.07%